AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05337007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate protein diet
Description: 48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
Study NCT05519423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Incentive Program
Description: Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
Study NCT05611203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: An Oropharyngeal swab
Description: An Oropharyngeal swab performed for diagnostic purposes
Study NCT06339723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pecha Kucha
Description: Pecha Kucha Method training was given
Study NCT05548231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC
Study NCT05548231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05373329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sanvello (app)
Description: Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation.
Study NCT05678309 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: At inclusion :~* 52.5 ml of blood :~* 24 ml plasma~* 20 ml serum~* 6 ml DNA~* 2.5 ml RNA
Study NCT05678309 — intervention group
Intervention type: OTHER
Intervention: skin swab sample
Description: At inclusion a skin swab sample will be collected
Study NCT05678309 — intervention group
Intervention type: OTHER
Intervention: skin biopsy sample
Description: At inclusion a skin biopsy sample will be collected
Study NCT05642325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamikibart
Description: Participants will receive vamikibart IVT injection
Study NCT05642325 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants will receive a sham procedure that mimics an IVT injection.
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 5 mg
Description: Korean / 3 on BnH-015B, 1 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 10 mg
Description: Korean / 6 on BnH-015B, 2 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 20 mg
Description: Korean / 6 on BnH-015B, 2 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 40 mg (Dietary impact)
Description: Korean / 6 on BnH-015B, 2 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 40 mg
Description: Caucasian / 6 on BnH-015B, 2 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 80 mg
Description: Korean / 6 on BnH-015B, 2 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 160 mg
Description: Korean / 6 on BnH-015B, 2 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 40 mg (MAD)
Description: Korean / 6 on BnH-015B, 2 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 80 mg (MAD)
Description: Korean / 6 on BnH-015B, 2 on placebo
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 40 mg (Part II)
Description: Korean / 9 subjects
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 80 mg (Part II)
Description: Korean / 9 subjects
Study NCT06535308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BnH-015B Placebo (Part II)
Description: Korean / 6 subjects
Study NCT05344378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATTAIN NAV Technology-Enhanced Family Navigation Model
Description: The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.
Study NCT05431270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT199
Description: PT199 is an anti-CD73 mAb with a differentiated mechanism of action.
Study NCT05678309 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: At inclusion, at 6 months and every year, the patient will respond to 5 questionnaires : Brest questionnaire, 5-D itch scale, Dermatology Life Quality Index, Itchy Quality of Life and Hospital Anxiety and Depression Scale
Study NCT04470674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab 1500 mg
Study NCT04470674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg
Study NCT04470674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC 5
Study NCT04470674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed 500 mg/m2
Study NCT05431270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.
Study NCT05431270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + nab-Paclitaxel
Description: Dosing is per Standard of Care.
Study NCT05431270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Dosing is per Standard of Care.
Study NCT05431270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Dosing is per Standard of Care.
Study NCT05431270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dosing is per Standard of Care.
Study NCT05431270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Pemetrexed
Description: Dosing is per Standard of Care.
Study NCT05431270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Carboplatin + Pemetrexed
Description: Dosing is per Standard of Care.
Study NCT04871893 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: multiECCO2R blood-gas exchanger
Description: Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
Study NCT05361187 — intervention group
Intervention type: DEVICE
Intervention: BOBBY™ Balloon Guide Catheter intended for use in neurovascular procedures, performing or as an adjunctive device
Description: The BOBBY™ BGC used during a mechanical thrombectomy procedure (stent retriever alone, contact aspiration alone or stent retriever and contact aspiration) and according to the instruction for use (IFU).
Study NCT06157216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRD-guided therapy
Description: MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
Study NCT05592366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Partner Hospital Assessment Tool
Description: Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
Study NCT05141006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Injection into the bladder
Study NCT05141006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BOTOX
Description: Injection into the bladder
Study NCT05141006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BOTOX
Description: Injection into the bladder
Study NCT05806788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binge Eating Syndrome Treatment (BESTOW)
Description: The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
Study NCT06203795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation dosing
Description: Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday
Study NCT06203795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
Study NCT05115734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum acylcarnitine profiling
Description: Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA).
Study NCT04937829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912
Study NCT04937829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05443932 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Description: 10mg Dapagliflozin daily for 8 weeks
Study NCT05443932 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Description: 50mg Hydrochlorothiazide daily for 8 weeks
Study NCT05354752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 7 days
Study NCT05354752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Placebo tablets
Description: VC005 placebo groups repeat administration for 7 days
Study NCT05270460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS12852
Description: PCS12852 oral tablet administered once daily
Study NCT05270460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator oral tablet administered once daily
Study NCT06203795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of the dialysis session
Description: Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday
Study NCT06203795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choice of the hemodialyzer
Description: Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
Study NCT05276544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention: Preparation and follow-up of diet program.
Study NCT04913103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: treatment by a study drug polatuzumab-vedotin, i.v.
Study NCT06330584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray 0 mg/spray
Description: A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0 mg midazolam/spray) in each nostril, i.e., no active compound
Study NCT06330584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Nasal Spray 0.45 mg/spray
Description: A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.45 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 0.9 mg
Study NCT06330584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Nasal Spray 0.9 mg/spray
Description: A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.9 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 1.8 mg
Study NCT06006507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: no exercise will be given
Study NCT06006507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
Study NCT04913103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: treatment by a study drug bendamustin i.v.
Study NCT04913103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: treatment by a study drug rituximab, i.v.
Study NCT06405061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab: 1200 mg, IV, q3w
Study NCT05733624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCAI-001 0.01% eyedrop
Description: BID for 12weeks
Study NCT05733624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCAI-001 0.02% eyedrop
Description: BID for 12weeks
Study NCT05733624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis 0.05% eyedrop
Description: BID for 12weeks
Study NCT05320523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.
Description: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
Study NCT05320523 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.
Description: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
Study NCT05320523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GPi stimulation
Description: Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
Study NCT05320523 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GPi stimulation
Description: Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
Study NCT05320523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBM stimulation
Description: Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system
Study NCT05320523 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
Study NCT06332651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: Black beans cooked and mashed and amino acid mixture as liquid drink to make methionine the limiting amino acid in the food consumed
Study NCT06332651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Skimmed milk as liquid drink and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
Study NCT06332651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorghum
Description: Sorghum cooked and mashed and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
Study NCT06090279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OmniFlow Breathing Therapy BioFeeback System
Description: FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab. Each game usage itself is expected to last 15-20 minutes.
Study NCT04737343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
Study NCT04737343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine Tablets
Description: Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
Study NCT05201560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol Tartrate Injection
Description: Patients of this group will receive Butorphanol Tartrate Injection
Study NCT05201560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients of this group will receive Fentanyl
Study NCT06506955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: futibatinib
Description: TAS-120 futibatinib monotherapy
Study NCT06506955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: futibatinib, fulvestrant
Description: TAS-120 futibatinib combination therapy with fulvestrant
Study NCT05142254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 2.5-5 mg/day
Study NCT05142254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxyurea
Description: 20 mg/kg/day
Study NCT05142254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 20 mg/kg/day
Study NCT05142254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
Study NCT06202287 — intervention group
Intervention type: OTHER
Intervention: Balance measurements using the HUR Smart balance device, balance tests, and other surveys.
Description: 50 stroke patients will undergo balance measurements using the HUR Smart balance device and other tests.
Study NCT05978388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation
Description: Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
Study NCT04397159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination Exercise
Description: Flywheel Resistance Plus Aerobic Exercise
Study NCT06116422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grocery intervention - unrestricted
Description: Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).
Study NCT06116422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grocery intervention - restricted
Description: Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
Study NCT05986240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
Study NCT05986240 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Danvatirsen + Venetoclax
Description: Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells.
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Given PO
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib camsylate
Description: Given PO
Study NCT04455750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO